Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses

Innate Immunity

Volumn 20, Issue 3, 2014, Pages 249-260

  Lofrumento, Dario D ^a   Nicolardi, Giuseppe ^a   Cianciulli, Antonia ^b   Nuccio, Francesco De ^a   Pesa, Velia La ^a   Carofiglio, Vito ^b   Dragone, Teresa ^b   Calvello, Rosa ^b   Panaro, Maria A ^b  

^a UNIVERSITY OF SALENTO   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

cytokine; dopaminergic neuron; Parkinson's disease; resveratrol; SOCS 1

Indexed keywords

CD11 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; NEUROPROTECTIVE AGENT; RESVERATROL; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; CYTOKINE; SOCS1 PROTEIN, MOUSE; STILBENE DERIVATIVE; SUPPRESSOR OF CYTOKINE SIGNALING; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GENE EXPRESSION; GLIA CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GLIA; IMMUNOLOGY; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; MPTP POISONING; NEOSTRIATUM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

ANIMALS; CYTOKINES; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEOSTRIATUM; NEUROGLIA; NEUROPROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; STILBENES; SUBSTANTIA NIGRA; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 84898986648     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913488429     Document Type: Article

References (54)

1. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008 ; 359: 2468-2476
2. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002 ; 175: 303-317
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 ; 20: 415-455
4. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003 ; 39: 889-909
5. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive forHLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988 ; 38: 1285-1291
6. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007 ; 208: 1-25
7. Kim W, De Vellis S. Microglia in health and disease. J Neurosci Res. 2005 ; 81: 302-313
8. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994 ; 165: 208-210
9. Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl. 2000 ; 58: 143-151
10. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci. 2000 ; 16: 724-739
11. Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol. 2008 ; 181: 3167-3176
12. Frémont L. Biological effects of resveratrol. Life Sci. 2000 ; 66: 663-673
13. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. Mutat Res. 2008 ; 658: 68-94
14. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009 ; 54: 111-118
15. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005 ; 280: 37377-37382
16. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem. 2010 ; 285: 9100-9113
17. Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol. 2007 ; 73: 550-560
18. Chao J, Yu MS, Ho YS, Wang M, Chang RC. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. 2008 ; 45: 1019-1026
19. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol. 2010 ; 636: 1-7
20. Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, Panaro MA. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation. 2011 ; 18: 79-88
21. Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 1243-1250
22. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010 ; 1328: 139-151
23. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008 ; 600: 78-82
24. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, Forno LS. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 1986 ; 376: 117-124
25. Banerjee R, Sreetama S, Saravanan KS, Chandra G, Nath De S, Mohanakumar KP. Intrastriatal infusion of the Parkinsonian neurotoxin, MPP(+), induces damage of striatal cell nuclei in Sprague-Dawley rats. J Chem Neuroanat. 2006 ; 32: 90-100
26. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007 ; 2: 141-151
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
28. Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol. 2010 ; 41: 375-383
29. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002 ; 958: 439-447
30. Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci. 2012 ; 69: 1153-1165
31. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun. 2002 ; 297: 700-713
32. Kundu JK, Shin YK, Kim SH, Surh YJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis. 2006 ; 27: 1465-1474
33. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem. 2004 ; 12: 5571-5578
34. Leiro J, Alvarez E, Arranz JA, Laguna R, Uriarte E, Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol. 2004 ; 75: 1156-1165
35. Eskan MA, Benakanakere MR, Rose BG, Zhang P, Zhao J, Stathopoulou P, et al. Interleukin-1beta modulates proinflammatory cytokine production in human epithelial cells. Infect Immun. 2008 ; 76: 2080-2089
36. Judd AM, Call GB, Barney M, McIlmoil CJ, Balls AG, Adams A, Oliveira GK. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci. 2000 ; 917: 628-637
37. Gibson RM, Rothwell NJ, Le Feuvre RA. CNS injury: the role of the cytokine IL-1. Vet J. 2004 ; 168: 230-237
38. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 ; 5: 629-640
39. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans. 2007 ; 35: 1122-1126
40. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, Gerlo S. Interleukin-6, a mental cytokine. Brain Res Rev. 2011 ; 67: 157-183
41. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012 ; 87: 10-20
42. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007 ; 55: 453-462
43. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008 ; 5: 8-8
44. Panaro MA, Cianciulli A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease. Curr Pharm Des. 2012 ; 18: 200-208
45. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 2004 ; 25: 434-440
46. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005 ; 7: 100-110
47. Yang MS, Min KJ, Joe E. Multiple mechanisms that prevent excessive brain inflammation. J Neurosci Res. 2007 ; 85: 2298-2305
48. Polizzotto MN, Bartlett PF, Turnley AM. Expression of "suppressor of cytokine signalling" (SOCS) genes in the developing and adult mouse nervous system. J Comp Neurol. 2000 ; 423: 348-358
49. Maier J, Kincaid C, Pagenstecher A, Campbell IL. Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis. Am J Pathol. 2002 ; 160: 271-288
50. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997 ; 387: 917-921
51. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997 ; 387: 921-924
52. O'Keefe GM, Nguyen VT, Ping Tang LL, Benveniste EN. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J Immunol. 2001 ; 166: 2260-2269
53. Wesemann DR, Dong Y, O'Keefe GM, Nguyen VT, Benveniste EN. Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages. J Immunol. 2002 ; 169: 2354-2360
54. Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J Immunol. 2004 ; 172: 7510-7518